drugset / Trial / NCT05157100

Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia

NCT05157100

Phase 4 Completed 20 enrolled The Orthopedic Foundation
NaSingle-groupOpen-labelTreatment

Summary

Study of Ingrezza (Valbenazine) for the treatment of cervical dystonia.

Timeline

Start
2021-10-19
Primary completion
2023-09-15
Completion
2023-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Valbenazine Small molecule 40 mg Oral
Subject Valbenazine Small molecule 80 mg Oral

Indications